Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 11

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 11
---
 used technology licensed from Medarex to generate the TF antibody forming part of tisotumab vedotin. Tisotumab vedotin, marketed as Tivdak, is the first and only ADC approved for the treatment of adult patients with recurrent or metastatic cervical cancer after prior therapy in the U.S., Europe and Japan. Tisotumab vedotin is being co-developed by Genmab and Pfizer. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the U.S. and is leading commercial operational activities in Japan, Europe and all other regions globally, excluding the United States and the China region. Pfizer is leading commercial operational activities in the U.S. and will lead commercial operational

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 8/44                   
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
activities in China once approved in connection with the sublicense of its rights to develop and commercialize tisotumab vedotin in China to Zai Lab. Genmab will record sales for Europe, Japan and rest of world markets (excluding the United States and the China region), and will provide royalties in the low teens to Pfizer on net sales. The companies have joint decision-making power on the worldwide development and commercialization strategy for Tivdak. Please consult the U.S. Prescribing Information and the European Summary of Product Characteristics for the labeled indication and safety information for Tivdak.

Rinatabart Sesutecan (Rina-S, GEN1184) – Potential best-in-class FRα-targeted topoisomerase I (TOPO1) ADC

• FRα-targeted TOPO1 ADC being evaluated for potential treatment of FRα-expressing cancers

• Phase 3 clinical trial (NCT06619236) in PROC is recruiting

• Additional trials announced including Phase 3 trials in second line plus endometrial cancer, second line platinum sensitive ovarian cancer (PSOC), and a planned Phase 2 trial in NSCLC

Rina-S is a novel FRα-targeted TOPO1 ADC being evaluated for the potential treatment of ovarian cancer and other FRα-expressing cancers